Tumor marker expression is predictive of survival in patients with esophageal cancer Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen.

Slides:

Advertisements

Similar presentations

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Advertisements

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients Danielle K. Farrington, MD, Patrick D. Kilgo,

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD

Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M

Clinicopathological and biological assessment of lung cancers with pleural dissemination Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability? Tirone E. David, MD, Susan Armstrong, MS,

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Lars P. Riber, MD, PhD, Thomas D. Christensen,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Complications and Risk Assessment of 25 Years in Pediatric Pacing

Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi Shibuya, MD, Tetsuya.

Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.

Surgery for coarctation of the aorta in infants weighing less than 2 kg Emile A Bacha, MD, Melvin Almodovar, MD, David L Wessel, MD, David Zurakowski,

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung Cancer Katsuhiko Matsuyama, Yukio Chiba, Masato Sasaki, Hirokazu Tanaka, Ryusuke.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Stereotactic Radiosurgery/Stereotactic Body Radiotherapy for Recurrent Lung Neoplasm: An Analysis of Outcomes in 100 Patients Arjun Pennathur, MD, James.

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer Paul J. Speicher, MD, Zachary W. Fitch,

Castigliano M. Bhamidipati, DO, MS, George J

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma Masahiro Yasunaga,

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,

Lucas W. Thornblade, MD, MPH, Michael S

Operative Results and Outcomes in Children With Shone's Anomaly

Complex Esophageal Reconstruction Procedures Have Acceptable Outcomes Compared With Routine Esophagectomy Jessica M. Moore, BS, Craig M. Hooker, PhD,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Deregulated p21WAF1 Overexpression Impacts Survival of Surgically Resected Esophageal Squamous Cell Carcinoma Patients Yih-Gang Goan, MD, Hon-Ki Hsu,

Anthony Lemaire, MD, William R

Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Population- Based Analysis Babatunde A. Yerokun, MD, Zhifei Sun, MD, Chi-Fu Jeffrey.

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Total Arterial Revascularization: A Superior Strategy for Diabetic Patients Who Require Coronary Surgery James Tatoulis, MD, FRACS, Rochelle Wynne, PhD,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Atrioventricular valve regurgitation in patients with single ventricle: impact of the bidirectional cavopulmonary anastomosis William T Mahle, MD, Meryl.

Ross Versus Non-Ross Aortic Valve Replacement in Children: A 22-Year Single Institution Comparison of Outcomes John W. Brown, MD, Parth M. Patel, BS,

Use of Amiodarone After Major Lung Resection

Quality of life outcomes are equivalent after lobectomy in the elderly

Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence Balu Bhaskar, MD, FCICM, Joel Dulhunty, PhD,

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Risk Factors for Atrial Fibrillation After Lung Cancer Surgery: Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database Mark Onaitis,

Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Pretransplant Panel Reactive Antibodies in Human Lung Transplantation: An Analysis of Over 10,000 Patients Ashish S. Shah, MD, Lois Nwakanma, MD, Christopher.

Listing Low-Weight or Ill Infants for Heart Transplantation: Is It Prudent? Raheel Rizwan, MD, Farhan Zafar, MD, Clifford Chin, MD, James Tweddell, MD,

Attila Dubecz, MD, Thomas J. Watson, MD, Daniel P

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

The Prognostic Importance of Immunohistochemically Detected Node Metastases in Resected Esophageal Adenocarcinoma Tara A. Waterman, BA, Jeffrey A. Hagen,

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD,

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Prolonged Intensive Care Unit Stay in Cardiac Surgery: Risk Factors and Long-Term- Survival Ortrud Vargas Hein, MD, Jürgen Birnbaum, MD, Klaus Wernecke,

Aortic valve replacement: comparison of late survival between autografts and homografts Christopher J Knott-Craig, MD, Ronald C Elkins, MD, KathyLee.

Left-Sided Reoperations After Arterial Switch Operation: A European Multicenter Study Vladimiro L. Vida, MD, PhD, Lorenza Zanotto, MD, Lucia Zanotto,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma Kuang-Tai Kuo, MD, Kuan-Chih Chow, PhD, Yu-Chung.

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

Creation of a Quantitative Score to Predict the Need for Mechanical Support in Children Awaiting Heart Transplant Ryan R. Davies, MD, Shylah Haldeman,

Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients Christine L Lau, MD, Scott M Palmer, MD, Katherine E.

Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy Arjun Pennathur, MD, Andrew Farkas, BA, Alyssa.

Left Ventricular End-Diastolic Pressure Predicts Survival in Coronary Artery Bypass Graft Surgery Patients Jeevan Nagendran, MD, PhD, Colleen M. Norris,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Tumor marker expression is predictive of survival in patients with esophageal cancer Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen Allegra, PhD, Mary-Beth H Moore, BA, James E Herndon, PhD, Thomas A D’Amico, MD The Annals of Thoracic Surgery Volume 72, Issue 3, Pages 859-866 (September 2001) DOI: 10.1016/S0003-4975(01)02838-7

Fig 1 Representative samples of immunohistochemically stained esophageal tumor specimens. Areas of brown coloration indicate immunohistochemical marker staining. Antibodies included are (clockwise from upper left) p53, Her2-neu, glutathione S-transferase-π, and P-glycoprotein. All photomicrographs were imaged at ×40. (GST-π = glutathione S-transferase-π; P-gp = p-glycoprotein.) The Annals of Thoracic Surgery 2001 72, 859-866DOI: (10.1016/S0003-4975(01)02838-7)

Fig 2 Cancer-specific survival analysis for the entire cohort plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. The Annals of Thoracic Surgery 2001 72, 859-866DOI: (10.1016/S0003-4975(01)02838-7)

Fig 3 Cancer-specific survival analysis comparing patients with T1, T2, and T3 esophageal tumors plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. The Annals of Thoracic Surgery 2001 72, 859-866DOI: (10.1016/S0003-4975(01)02838-7)

Fig 4 (A) Cancer-specific survival analysis comparing patients with low-level expression of P-glycoprotein (P-gp) versus those with P-glycoprotein high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (B) Cancer-specific survival analysis comparing patients with low-level expression of transforming growth factor-α (TGF-α) versus those with transforming growth factor-α high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (C) Cancer-specific survival analysis comparing patients with low-level expression of glutathione S-transferase-π (GST-π) versus those with glutathione S-transferase-π high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (D) Cancer-specific survival analysis comparing patients with low-level expression of p53 versus those with p53 high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (E) Cancer-specific survival analysis comparing patients with low expression of factor VIII versus those with factor VIII high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. The Annals of Thoracic Surgery 2001 72, 859-866DOI: (10.1016/S0003-4975(01)02838-7)

Fig 5 Cancer-specific survival analysis comparing patient groups determined by the number of negative prognostic markers present (0, 1 to 2, 3, and 4 markers), plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. The Annals of Thoracic Surgery 2001 72, 859-866DOI: (10.1016/S0003-4975(01)02838-7)